Piper Sandler Maintains Overweight on Allogene Therapeutics, Raises Price Target to $8
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and raises the price target from $7 to $8.
Login to comment